Tirzepatide and semaglutide are both GLP-1 medications but they work differently and drive different lab results. Here is exactly what to expect from each on your blood work.
Quick Summary - Tirzepatide is a dual GIP/GLP-1 agonist -- semaglutide is GLP-1 only -- this difference drives meaningfully different lab outcomes - Tirzepatide produces greater weight loss, better triglyceride reduction, and stronger HbA1c improvement on average - Semaglutide has a longer track record and more published long-term cardiovascular outcome data - Both require the same monitoring panel -- ApoB, HbA1c, fasting glucose, liver enzymes, triglycerides - Draw labs 48 hours after weekly injection, fasted, morning for both medications
Most people treat tirzepatide and semaglutide as interchangeable -- just two GLP-1 drugs at different price points. That is not accurate. They work through different receptor systems, and the difference matters for what shows up in your labs.
Semaglutide is a GLP-1 receptor agonist only. It mimics the action of naturally occurring GLP-1 -- the gut hormone that tells the pancreas to release insulin, signals the brain to reduce appetite, and slows gastric emptying.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. In addition to GLP-1 receptor activity, it also agonizes the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone that enhances insulin secretion and, crucially, has direct effects on fat tissue metabolism that GLP-1 does not.
The GIP component of tirzepatide appears to be responsible for its superior lipid effects and possibly its greater weight loss. Understanding this distinction helps predict what your labs will show on each medication.
Weight loss (most important outcome for many users)
Semaglutide (STEP 1 trial): Mean 14.9% body weight reduction over 68 weeks at 2.4mg.
Tirzepatide (SURMOUNT-1 trial): Mean 20.9% body weight reduction over 72 weeks at 15mg.
Advantage: Tirzepatide -- significantly greater weight loss at comparable timepoints.
HbA1c reduction
Semaglutide: 1.5-2.0 percentage point reduction in T2D populations.
Tirzepatide: 2.0-2.5 percentage point reduction in T2D populations.
Advantage: Tirzepatide -- modestly greater glucose-lowering effect.
Triglycerides
Semaglutide: 15-25% reduction from baseline in most users.
Tirzepatide: 20-35% reduction from baseline -- the GIP component appears to have direct effects on hepatic triglyceride metabolism.
Advantage: Tirzepatide -- particularly for users with elevated baseline triglycerides.
ApoB
Semaglutide: 8-15 mg/dL reduction from baseline typical.
Tirzepatide: 10-18 mg/dL reduction -- likely driven by greater visceral fat reduction.
Advantage: Tirzepatide -- modestly greater ApoB reduction.
Liver enzymes (ALT)
Both medications produce meaningful ALT reduction in users with fatty liver. Tirzepatide may have a slight edge due to greater visceral fat reduction but direct comparisons are limited.
Advantage: Comparable, slight edge to tirzepatide.
Cardiovascular outcomes (long-term)
Semaglutide: Robust data from the SUSTAIN and SELECT trials showing significant reduction in major cardiovascular events.
Tirzepatide: Cardiovascular outcome trial data is emerging but not yet as extensive as semaglutide.
Advantage: Semaglutide -- more established long-term cardiovascular outcome data.
Regardless of which medication you are using, the lab monitoring panel is identical:
At baseline (before first dose): ApoB, HbA1c, fasting glucose, fasting insulin, complete metabolic panel (liver enzymes + kidney function), lipid panel, hs-CRP.
At 12 weeks: ApoB, HbA1c, fasting glucose, lipid panel, liver enzymes.
At 6 months: Full baseline panel repeated. Add thyroid if significant weight loss. Add testosterone and SHBG for men losing significant weight.
Draw timing for both: Fasted, morning, 48 or more hours after your weekly injection. Both are weekly medications and the same timing rules apply.
Both medications cause nausea, particularly during titration. Tirzepatide tends to cause more significant nausea in the early titration weeks due to the combined GIP/GLP-1 effect on gastric motility. Semaglutide nausea is generally more predictable and manageable.
For users who struggled with semaglutide nausea, tirzepatide may not be better and may be worse in the early weeks. BPC-157 (250-500 mcg daily) addresses both medications' nausea through the same mechanism -- NO pathway restoration and area postrema modulation.
For maximum metabolic impact and weight loss: Tirzepatide if tolerated and accessible.
For established long-term cardiovascular risk reduction with more evidence: Semaglutide.
For cost and access: Semaglutide compounded is more widely available and typically lower cost than tirzepatide compounded.
For users with significant hypertriglyceridemia: Tirzepatide -- the GIP-mediated triglyceride reduction is meaningful.
For users who had poor semaglutide response: Tirzepatide works through an additional receptor and may produce better results in GLP-1 partial non-responders.
Can I switch from semaglutide to tirzepatide?
Yes. Most practitioners recommend washing out for 1-2 weeks between medications, then starting tirzepatide at the lowest dose regardless of what dose of semaglutide you were on. Titrate from the beginning.
Are the lab improvements from tirzepatide permanent after stopping?
No. Lab values and weight loss from both medications return toward baseline after discontinuation, typically within 6-12 months. Both are intended as ongoing treatments, not short-term interventions.
Does tirzepatide affect IGF-1 like semaglutide does?
The GLP-1 component of tirzepatide has the same modest IGF-1 lowering effect seen with semaglutide. If combining with GH peptides, add IGF-1 to your monitoring panel regardless of which GLP-1 medication you are using.
Which medication is better for NAFLD/fatty liver?
Both are effective. Tirzepatide may have a modest edge due to greater visceral fat reduction, but both produce meaningful liver enzyme improvement in users with fatty liver. Track ALT to confirm your specific response.
Is it safe to combine tirzepatide with peptides like BPC-157?
BPC-157 combined with tirzepatide specifically for nausea management has extensive anecdotal support and strong mechanistic rationale. No significant interactions are known between tirzepatide and any of the commonly used peptides.
The information in this article is for educational purposes only. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any protocol.
Written by Ryan -- Founder, MyProtocolStack. Last Updated: April 2026.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →